Document is current
Any future updates will be listed below
-
Authors
Ortega-Ferreira, Céline
Soret, Perrine
Robin, Gautier https://orcid.org/0000-0002-0066-7759
Speca, Silvia https://orcid.org/0000-0001-8494-3329
Hubert, Sandra
Le Gall, Marianne
Desvaux, Emiko https://orcid.org/0000-0001-5544-9575
Jendoubi, Manel
Saint-Paul, Julie https://orcid.org/0000-0002-3659-3245
Chadli, Loubna
Chomel, Agnès
Berger, Sylvie
Nony, Emmanuel https://orcid.org/0000-0003-1820-8881
Neau, Béatrice
Fould, Benjamin
Licznar, Anne
Levasseur, Franck https://orcid.org/0009-0006-9721-4399
Guerrier, Thomas https://orcid.org/0000-0001-8232-9405
Elouej, Sahar
Courtade-Gaïani, Sophie https://orcid.org/0000-0001-8266-7893
Provost, Nicolas
Nguyen, The Quyen
Verdier, Julien
Launay, David https://orcid.org/0000-0003-1840-1817
De Ceuninck, Frédéric https://orcid.org/0000-0003-4331-1637
- License Information
-
More Information
Article History
Received: 28 October 2022
Accepted: 22 August 2023
First Online: 31 August 2023
Competing interests
: Servier is the owner of the described therapeutic Gal-3 mAbs for which a patent application (EP22305372) has been filed. G.R., M.L.G., and J.S. are regular employees of Mabqi, a company providing contract research services and having received fees from Servier for the generation of Gal-3 neutralizing mAbs (contract number CT0081211). D.L., S.S., M.J., and T.G. are employees of the Université de Lille, which received fees from Servier for conducting evaluations in the HOCl model (contract number CT0089360). D.L. is or has been a consultant for Actelion, Boehringer Ingelheim, Octapharma, CSL Behring, Takeda, and Servier. The following authors: C.O., P.S., S.H., L.C., A.C., S.B., E.N., B.N., B.F., A.L., F.L., S.E., S.C., N.P., T.Q.N., and F.D. were regular employees of Servier at the time the research project. E.D. was a Ph.D student financed by Servier at the time of the research project. J.V. was a post-doc financed by Servier at the time of the research project.
